Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.62 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.61 |
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | MMP9 | P14780 | 3/20 | 0.58 |
| ▸ | MMP8 | P22894 | 3/20 | 0.58 |
| ▸ | MMP1 | P03956 | 2/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | IL1RN | P18510 | 3/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720539 | 0.94 | ERAP2 (0.64) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL30050958 | 0.93 | ECE1 (0.63) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL30465916 | 0.92 | ERAP2 (0.64) | ECE1ERAP2ACEIL1RNERAP1 | |
| SCHEMBL31720355 | 0.92 | ECE1 (0.59) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL38662564 | 0.92 | ERAP2 (0.55) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL29851151 | 0.91 | ACE (0.57) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL30051190 | 0.91 | ECE1 (0.74) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL30051725 | 0.91 | EDNRA (0.60) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL31564765 | 0.90 | ECE1 (0.69) | ECE1ERAP2MMP2MMP9MMP8 | |
| SCHEMBL30052122 | 0.90 | ECE1 (0.69) | ECE1ERAP2MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727957-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042807-A1 | NEXT GENERATION ACTX PEPTIDES | Vestaron Corporation (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2025226701-A1 | PROTEOLYTICALLY STABLE U1-AGATOXIN-TA1B VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250188136-A1 | AV3 MUTANT POLYPEPTIDES FOR PEST CONTROL | SUTERRA LLC | 2025-06-12 | — | — | US | disclosed |
| WO-2025029828-A9 | OMEGA HEXATOXIN VARIANT PEPTIDES AND METHODS OF USE THEREOF | Vestaron Corporation (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025029828-A1 | OMEGA HEXATOXIN VARIANT PEPTIDES AND METHODS OF USE THEREOF | Vestaron Corporation (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4483718-A2 | PROTEOLYTICALLY STABLE U1-AGATOXIN-TA1B VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024259306-A2 | PVD1 VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4139334-B1 | PROTEOLYTICALLY STABLE U1-AGATOXIN-TA1B VARIANT POLYPEPTIDES FOR PEST CONTROL | VESTARON CORP (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240041038-A1 | INSECTICIDAL COMBINATIONS | Vestaron Corporation (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4314025-A2 | AV3 MUTANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024026406-A2 | Next Generation ACTX Peptides | Vestaron Corporation (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023245100-A1 | ANTIMICROBIAL NCR13 VARIANT PEPTIDES | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230337684-A1 | PROTEOLYTICALLY STABLE U1-AGATOXIN-TA1B VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2023-10-26 | — | — | US | disclosed |
| US-11713341-B1 | Antimicrobial NCR13 variant peptides | Vestaron Corporation (US) | 2023-08-01 | — | — | US | disclosed |
| US-11692016-B2 | High gene expression yeast strain | SUTERRA LLC | 2023-07-04 | — | — | US | disclosed |
| EP-4142498-A1 | INSECTICIDAL COMBINATIONS | Vestaron Corporation (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4139334-A2 | PROTEOLYTICALLY STABLE U1-AGATOXIN-TA1B VARIANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022212777-A2 | AV3 MUTANT POLYPEPTIDES FOR PEST CONTROL | Vestaron Corporation (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042807-A1 | NEXT GENERATION ACTX PEPTIDES | CRYAA, RNGTT, CALML3 | ECE1 3875/4885ERAP2 2184/4885MMP2 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.